Drug Type Small molecule drug |
Synonyms Metformin/MP-513, Metformin/teneligliptin, MP-513/metformin + [3] |
Target |
Mechanism DPP-4 inhibitors(Dipeptidyl peptidase IV inhibitors), PRKAB1 activators(Protein kinase AMP-activated non-catalytic subunit beta 1 activators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date KR (31 Mar 2015), |
Regulation- |
Molecular FormulaC4H12ClN5 |
InChIKeyOETHQSJEHLVLGH-UHFFFAOYSA-N |
CAS Registry1115-70-4 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Diabetes Mellitus, Type 2 | KR | 31 Mar 2015 |
Phase 2 | 448 | teneligliptin20+Teneligliptin+Metformin (Teneli 5mg+Met) | duwhbydzjq(ltftrnypuz) = klebzlqqzu nmcldwdmvo (qcqkcvvzgi, vvzvjqjkyx - xvzcuguuyq) View more | - | 01 Sep 2014 | ||
teneligliptin20+Teneligliptin+Metformin (Teneli 10mg+Met) | duwhbydzjq(ltftrnypuz) = jseycvvfnz nmcldwdmvo (qcqkcvvzgi, uxkuvtjald - bnpyhcqxli) View more |